{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:08:30Z","timestamp":1787612910265,"version":"build-2736575974"},"reference-count":127,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Novel therapies such as CAR-T, BTK inhibitors and PD-1 inhibitors have changed the management of aggressive B-cell lymphomas. Nonetheless, these novel therapies have their own risk of late toxicities including second malignancies. They also create a subgroup of patients with relapse, treatment failure, or indefinite maintenance. We discuss the current role of autologous and allogeneic stem cell transplantation in this context. In patients with recurrent diffuse large B-cell lymphoma, CAR-T cell treatment has largely replaced autologous transplant. Autologous transplant should be considered in patients with late relapses and in selected patients with T-cell-rich B-cell lymphoma, where CAR-T cell therapy may be less effective. It also remains the treatment of choice for consolidation of patients with primary CNS lymphoma. In mantle cell lymphoma, intensive chemotherapy combined with BTK inhibitors and rituximab results in excellent outcomes, and the role of autologous transplantation is declining. In Hodgkin\u2019s lymphoma, autologous transplant consolidation remains the standard of care for patients who failed initial chemotherapy. Allogeneic transplantation has lower relapse rates but more complications and higher non-relapse mortality than autologous transplantation. It is usually reserved for patients who fail autologous transplantation or in whom autologous stem cells cannot be collected. It may also have an important role in patients who fail CAR-T therapies. The increasing complexity of care and evolving sequencing of therapies for patients with aggressive B-cell lymphomas only emphasizes the importance of appropriate patient selection and optimal timing of stem cell transplantation.<\/jats:p>","DOI":"10.3390\/cells13211780","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:07:22Z","timestamp":1730092042000},"page":"1780","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma\u2014Is There Still a Role?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-6265","authenticated-orcid":false,"given":"Michael","family":"Daunov","sequence":"first","affiliation":[{"name":"University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[{"name":"University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,27]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute: Surveillance, Epidemiology, and End Results Program (2024, May 09). Cancer Stat Facts: Non-Hodgkin Lymphoma, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood.V14.5.503.503","article-title":"Autologous Bone Marrow Infusion as an Adjunct in Therapy of Malignant Disease","volume":"14","author":"McFarland","year":"1959","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(61)91720-2","article-title":"Nitrogen-mustard therapy combined with autologous marrow infusion","volume":"277","author":"Duff","year":"1961","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1537-2995.1962.tb00218.x","article-title":"Autologous and Isologous Bone Marrow Storage and Infusion in the Treatment of Myelo-Suppression","volume":"2","author":"Kurnick","year":"1962","journal-title":"Transfusion"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0002-9343(80)90472-6","article-title":"Dose: A critical factor in cancer chemotherapy","volume":"69","author":"Frei","year":"1980","journal-title":"Am. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/sj.bmt.1701271","article-title":"CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"21","author":"Soiffer","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2003.08.054","article-title":"Syngeneic hematopoietic stem-cell transplantation for Non-Hodgkin\u2019s lymphoma: A comparison with allogeneic and autologous transplantation\u2014The lymphoma working committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation","volume":"21","author":"Bierman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/10428194.2010.520777","article-title":"Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden","volume":"52","author":"Lazarevic","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1200\/JCO.2004.05.035","article-title":"Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin\u2019s Lymphoma","volume":"22","author":"Hoerr","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/annonc\/mdh090","article-title":"Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cellnon-Hodgkin\u2019s lymphoma: A single institution study","volume":"15","author":"Belhadj","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000088411","article-title":"The Significance of Minimal Residual Disease in Stem Cell Grafts and the Role of Purging: Is It Better to Purge in vivo or in vitro?","volume":"114","author":"Melillo","year":"2005","journal-title":"Acta Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(04)01646-8","article-title":"B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma","volume":"5","author":"Jacobsen","year":"2004","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJM199504203321601","article-title":"Comparison of CHOP Chemotherapy with Autologous Bone Marrow Transplantation for Slowly Responding Patients with Aggressive Non-Hodgkin\u2019 Lymphoma","volume":"332","author":"Verdonck","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF00273421","article-title":"Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: Toxicity and antitumor activity in 26 patients with poor-risk malignancies","volume":"22","author":"Gaspard","year":"1988","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbmt.2004.09.003","article-title":"High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed\/refractory lymphoma: An effective regimen with low morbidity and mortality","volume":"11","author":"Wadhwa","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdf109","article-title":"Risk of therapy-related myelodysplastic syndrome\/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"13","author":"Hosing","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.1999.01627.x","article-title":"Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT","volume":"106","author":"Milligan","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bbmt.2009.07.014","article-title":"Busulfan and Cyclophosphamide (Bu\/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience","volume":"15","author":"Ulrickson","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/sj.bmt.1705841","article-title":"Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu\/Cy\/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin\u2019s lymphoma","volume":"40","author":"Kim","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.bbmt.2010.07.016","article-title":"Andersson. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies","volume":"17","author":"Kebriaei","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bmt.1701322","article-title":"Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation","volume":"22","author":"Schuler","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3109\/10428194.2014.882504","article-title":"Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma","volume":"55","author":"Shin","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1111\/ajco.12610","article-title":"Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity","volume":"13","author":"Shi","year":"2017","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.1997.15.3.1131","article-title":"Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin\u2019s lymphoma: Updated results of the prospective study LNH87-2. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Haioun","year":"1997","journal-title":"JCO"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood.V90.10.3844","article-title":"Results of High-Dose Therapy and Autologous Bone Marrow\/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group","volume":"90","author":"Nademanee","year":"1997","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1200\/JCO.1993.11.5.931","article-title":"Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin\u2019s lymphoma in first remission: A pilot study","volume":"11","author":"Freedman","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma","volume":"336","author":"Gianni","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support","volume":"350","author":"Milpied","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jnci\/93.1.22","article-title":"Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin\u2019s Lymphoma: Randomized Phase III EORTC Study","volume":"93","author":"Zagonel","year":"2001","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/annonc\/mdl153","article-title":"Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: Results of the international randomized phase III trial (MISTRAL)","volume":"17","author":"Betticher","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.2003.01.117","article-title":"Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin\u2019s Lymphoma: An Italian Multicenter Randomized Trial","volume":"21","author":"Martelli","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma","volume":"20","author":"Gisselbrecht","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.1998.16.8.2796","article-title":"VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin\u2019s lymphoma: Results of a prospective randomized trial by the non-Hodgkin\u2019s Lymphoma Cooperative Study Group","volume":"16","author":"Santini","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin\u2019s Lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Cordeiro, A., Bezerra, E.D., Hirayama, A.V., Hill, J.A., Wu, Q.V., Voutsinas, J., Sorror, M.L., Turtle, C.J., Maloney, D.G., and Bar, M. (2020). Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biol. Blood Marrow Transplant.","DOI":"10.1016\/j.bbmt.2019.08.003"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: Analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood-2002-04-1261","article-title":"Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study","volume":"101","author":"Metayer","year":"2003","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.V95.5.1588.005k38_1588_1593","article-title":"Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors","volume":"95","author":"Krishnan","year":"2000","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Tarella, C., Passera, R., Magni, M., Benedetti, F., Rossi, A., Gueli, A., Patti, C., Parvis, G., Ciceri, F., and Gallamini, A. (2010). Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma. J. Clin. Oncol., 29.","DOI":"10.1200\/JCO.2010.28.9777"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"ref_55","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2020006464","article-title":"Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell\/histiocyte-rich large B-cell lymphoma","volume":"137","author":"Griffin","year":"2021","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1182\/blood.2020009148","article-title":"Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell\/histiocyte-rich large B-cell lymphoma","volume":"137","author":"Trujillo","year":"2021","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial-PubMed","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1200\/JCO.22.00491","article-title":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study","volume":"40","author":"Houillier","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1182\/bloodadvances.2022007011","article-title":"Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: An LOC network study","volume":"6","author":"Lesueur","year":"2022","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaoncol.2021.1074","article-title":"Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma","volume":"7","author":"Scordo","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(21)00195-2","article-title":"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: A post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial","volume":"8","author":"Zoellner","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: A Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Thieblemont","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: A randomised trial","volume":"359","author":"BP","year":"2002","journal-title":"Lancet"},{"key":"ref_68","first-page":"467","article-title":"Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin\u2019s Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d\u2019\u00c9tudes des Lymphomes de l\u2019Adulte H89 Trial","volume":"20","author":"Mounier","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2000.18.2.332","article-title":"Treatment of Primary Progressive Hodgkin\u2019s and Aggressive Non-Hodgkin\u2019s Lymphoma: Is There a Chance for Cure?","volume":"18","author":"Josting","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","article-title":"Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients","volume":"22","author":"Fenske","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/cncr.24845","article-title":"Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin\u2019s lymphoma","volume":"116","author":"Bishop","year":"2010","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: Pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bbmt.2005.04.005","article-title":"Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma","volume":"11","author":"Dean","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2141.1999.01666.x","article-title":"Allogeneic bone marrow transplantation in aggressive non-Hodgkin\u2019s lymphoma (excluding Burkitt and lymphoblastic lymphoma): A series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle","volume":"107","author":"Dhedin","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.2005.05755.x","article-title":"Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma","volume":"131","author":"Doocey","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin\u2019s lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","article-title":"Low non-relapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: Report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"16","author":"Sirvent","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","article-title":"A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large BCell Lymphoma: A Report from the CIBMTR","volume":"16","author":"Lazarus","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: An analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"Canals","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00277-011-1395-9","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study","volume":"91","author":"Rigacci","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: Myeloablative or reduced intensity?","volume":"120","author":"EK","year":"2012","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","article-title":"Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic Transplantation Provides Durable Remission in a Subset of DLBCL Patients Relapsing after Autologous Transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin\u2019s lymphoma","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bmt.1702625","article-title":"Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin\u2019s lymphoma (NHL): Results of a provincial strategy. Ontario BMT Network, Canada","volume":"26","author":"Schimmer","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.bmt.1700614","article-title":"Bone marrow transplantation after failure of autologous transplant for non-Hodgkin\u2019s lymphoma","volume":"19","author":"Giralt","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/10428194.2010.538777","article-title":"T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse","volume":"52","author":"Kenkre","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamaoncol.2020.1278","article-title":"Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant","volume":"6","author":"Ghosh","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma molecular remissions and evidence of graft-vers","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bmt.1702392","article-title":"ORR Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma","volume":"25","author":"Nagler","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbmt.2014.11.673","article-title":"Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: An analysis of outcomes from the British Society of Blood and Marrow Transplantation","volume":"21","author":"Truelove","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a010369","article-title":"Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma","volume":"10","author":"Przepiorka","year":"1999","journal-title":"Ann. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","article-title":"Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): An open-label, randomised, phase 2 trial","volume":"15","author":"Glass","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","article-title":"Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin\u2019s lymphoma in recent years: A retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Boumendil","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman","year":"2021","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, non-relapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: Comparing 2003\u20132007 vs. 2013\u20132017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis","volume":"388","author":"Hamadani","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Shah, N.N., and Hamadani, M. (2021). Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.20.01447"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/blood-2009-11-255182","article-title":"Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma","volume":"115","author":"Lambert","year":"2010","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect","volume":"19","author":"Giralt","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/10428190290017051","article-title":"Graft versus Burkitt\u2019s lymphoma effect after allogeneic marrow transplantation","volume":"43","author":"Grigg","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study\u2014A prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Epperla, N., Ahn, K.W., Khanal, M., Litovich, C., Ahmed, S., Ghosh, N., Fenske, T.S., Kharfan-Dabaja, M.A., Sureda, A., and Hamadani, M. (2021). Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Transplant. Cell. Ther., 27.","DOI":"10.1016\/j.bbmt.2020.09.014"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","article-title":"Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation","volume":"77","author":"Jones","year":"1991","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","article-title":"Bone marrow transplants from HLA-identical siblings in advanced Hodgkin\u2019s disease","volume":"14","author":"Gajewski","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin\u2019s disease. European Group for Blood and Bone Marrow Transplantation","volume":"14","author":"Milpied","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2010.32.1711","article-title":"Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell\u2013Depleted Allogeneic Transplantation for Hodgkin\u2019s Lymphoma","volume":"29","author":"Peggs","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2012.318","article-title":"A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma","volume":"27","author":"Thomson","year":"2013","journal-title":"Leukemia"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: A prospective phase 2 multi-cohort study","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post\u2013allogeneic hematopoietic cell transplant: High response rate but frequent, GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: A DESCAR-T analysis","volume":"140","author":"Bachy","year":"2022","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtct.2022.10.026","article-title":"Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma","volume":"29","author":"Fried","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world Evidence of Axicabtagene Ciloleucel for the Treatment of Large B-Cell Lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: A model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/21\/1780\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:21:45Z","timestamp":1760113305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/21\/1780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,27]]},"references-count":127,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["cells13211780"],"URL":"https:\/\/doi.org\/10.3390\/cells13211780","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,27]]}}}